References

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

10.1038/s41391-018-0121-2 · 2019 · External reference

Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial

10.1016/j.eururo.2020.04.061 · 2020 · External reference

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

10.1016/s1470-2045(14)71205-7 · 2015 · External reference

Unresolved reference

External reference

Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors

10.1007/s12325-021-01823-6 · 2021 · External reference

Abiraterone and olaparib for metastatic castration-resistant prostate cancer

10.1056/evidoa2200043 · 2022 · External reference

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

10.1016/s1470-2045(23)00382-0 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument

10.1016/s0090-4295(97)00459-7 · 1997 · External reference

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

10.1186/1477-7525-1-79 · 2003 · External reference

Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer

10.1111/j.1524-4733.2008.00409.x · 2009 · External reference

Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial

10.1200/jco.2023.41.16_suppl.5012 · 2023 · External reference

Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the Phase 3 PROpel trial

10.1016/j.euo.2024.03.006 · 2024 · External reference

Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer

10.1200/jco.22.01649 · 2023 · External reference

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)01055-3 · 2023 · External reference

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

10.1016/s0140-6736(25)00684-1 · 2025 · External reference

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

10.1016/s0140-6736(25)00683-x · 2025 · External reference

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

10.1038/s41591-023-02704-x · 2024 · External reference